Home / People / Tomáš Matĕjovský
Picture of Tomas Matejovsky

Tomáš Matĕjovský

Partner
Head of Commercial, Regulatory and Disputes

CMS Cameron McKenna Nabarro Olswang, advokáti, v.o.s.
Palladium, Na Poříčí 1079/3a
110 00 Prague 1
Czech Republic
Languages French, English, Czech
Commercial

Tomáš Matĕjovský is a partner and the Head of the Commercial, Regulatory and Disputes practice at CMS Prague.

He focuses on litigation and arbitration, compliance matters and white collar crime, and on commercial law, including employment, IP and competition. As part of his practice he represents clients in various types of litigations and arbitration proceedings at all levels, such as commercial, unfair competition and damage claim disputes before regional courts, Superior Courts, the Supreme Court, and the Constitutional Court and various arbitration bodies.

Tomáš also advises Czech and international companies on sector specific regulatory issues with particular focus on highly regulated industries such as the life sciences & healthcare, technology, media and communications sectors. His clients include major multinationals in these sectors.

In addition, he also supports clients on negotiating complex commercial agreements and advises on investments and investment incentives schemes in the CEE region.

more less

"Great knowledge of the legal system and excellent communication skills."

Chambers

Relevant experience

  • The Austrian and Slovak subsidiaries of Siemens in a major cross-border dispute over alleged pre-tender contractual liabilities linked to an important bidding process for railway security equipment.
  • Eastern Sugar in the Czech Republic in a EUR 41m claim against the Czech Republic.
  • Ministry of Agriculture concerning a wrongful allocation of its sugar quota and related significant ECHR claim against the Czech Republic.
  • Ministry of Finance of the Czech Republic in a significant arbitration valued at EUR 78.8m against a shareholder of a major Czech coal producer relating to a possible breach of a privatisation agreement by which the state's share was sold.
  • Global technology company and its insurers in a major multimillion euro damage claims regarding delivery and use of faulty electrical devices that caused a fire in one of the Prague’s main shopping gallery and office space in the centre of town, therefore representing a major health and safety risk.
  • A major telecommunications operator on the first stand-alone competition dispute with a competitor regarding margin squeeze in respect to providing of and access to broadband xDSL internet.
  • Diageo on the Czech regulation of food products and beverages, including labelling and packaging advice and distribution arrangements advice.
  • A leading biopharmaceutical company on all matters, including advising on employment law and lifesciences sector specific regulatory matters.
  • A global software company on several cyber-squatting and domain name matters and disputes as well as on trademark infringement issues, including oppositions against trademark applications.
  • A global IT company on several criminal investigations in relation to alleged bribery and corruption issues.
  • Worldwide medical devices producer on several compliance and anti-corruption investigations and relating matters. 
more less

Education

  • 1999 - International Law and State Administration Course, Ecole National d'Administration, Paris, France
  • 1998 - European Law, History and French Course, Universite de Perpignan, Perpignan, France
  • 1997 - Law Degree, Charles University, Prague
more less

Memberships

  • Czech Bar Association
  • ALAI Czech Republic
more less
Life Sciences & Healthcare

Tomáš Matĕjovský is a partner and the CEE Head of the Lifesciences & Healthcare sector group as well as Head of the Commercial, Regulatory and Disputes practice at CMS Prague.

He focuses on litigation and arbitration, compliance matters and white collar crime, and on commercial law, including employment, IP and competition. As part of his practice he represents clients in various types of litigations and arbitration proceedings at all levels, such as commercial, unfair competition and damage claim disputes before regional courts, Superior Courts, the Supreme Court, and the Constitutional Court and various arbitration bodies.

Tomáš advises various medical devices and pharmaceutical companies on various issues, including sector-specific regulatory matters, clinical trial problems and anti-corruption issues, as well as general commercial advice regarding company start-ups, distribution agreements and general day-to-day advice. He also advises on sector-specific regulatory issues in various due diligence processes.

In addition, he also supports clients on negotiating complex commercial agreements and advises on investments and investment incentives schemes in the CEE region.

more less

Relevant experience

  • A global pharmaceutical company | on regulatory data and patent protection against generics entry in the Czech Republic.
  • An original drug manufacturer | on regulatory data protection in the Czech Republic.
  • A French biopharmaceutical company | on its entry to the Czech market as well as on specific regulatory matters, including marketing authorisations relating to their pharmaceutical products, intellectual property rights with regards to trademarks, distribution in the Czech Republic, the establishment of distribution businesses in the Czech Republic and in Slovakia. This has included advising on structuring of the most efficient distribution models for both countries.
  • A global pharmaceutical corporation | on an internal investigation related to potential misconduct of their former Czech managing director, who was accused of unjustified preferential treatment, bossing some other employees and uneconomical conduct to the detriment of the company. We did a thorough audit of mailboxes of certain employees, conducted interviews with some of the employees and assisted the internal investigators of the corporation with some other tasks (review of accounting documents etc.).
  • A French biopharmaceutical company | on several proceedings against the Czech State Institute for Pharmaceuticals Control.
  • Various pharmaceutical companies | on various issues concerning public procurement issues in relation to public tenders, due diligence in public tender contracts, their participation in public tenders or their representation in administrative proceedings.
  • A pharmaceutical company | on distribution models (DTP), parallel trade issues as well as public procurement in the Czech Republic.
  • A global manufacturer of medical devices | providing ongoing legal advice to, pharmaceutical and consumer packaged goods on commercial law matters, including distribution systems and strategies, rebates as well as abuse of dominance.
  • A global medical products and technologies company | on pricing and reimbursement
  • A multinational biopharmaceutical company | in respect of its liability in the course of clinical trials of pharmaceuticals.
  • A multinational pharmaceutical company | in respect of a liability claim concerning defective medicinal product (vaccine).
more less

Education

  • 1999 - International Law and State Administration Course, Ecole National d'Administration, Paris, France
  • 1998 - European Law, History and French Course, Universite de Perpignan, Perpignan, France
  • 1997 - Law Degree, Charles University, Prague
more less

Memberships

  • Czech Bar Association
  • ALAI Czech Republic
more less

Feed

Show only
1 July 2020
Sign­ing with e-sig­na­ture in CEE
This guide fo­cuses on the most im­port­ant leg­al areas where elec­tron­ic sig­na­tures are usu­ally used: em­ploy­ment law, com­mer­cial con­tracts, real es­tate law, cor­por­ate law and bank­ing and fin­ance con­tracts. This guide ad­di­tion­ally in­cludes help­ful at-a-glance
22 July 2020
CMS Ex­pert Guide to e-sig­na­tures in com­mer­cial con­tracts
This CMS Ex­pert Guide fo­cuses on com­mer­cial con­tracts where elec­tron­ic sig­na­tures are used. It in­cludes an over­view that com­pares the dif­fer­ent leg­al situ­ations and uses of e-sig­na­tures across each of the in­ter­na­tion­al jur­is­dic­tions.
14 September 2020
Czech Re­pub­lic pro­poses new rules on ad­vert­ising med­ic­al devices
The Czech Ad­vert­ise­ment Act is cur­rently un­der­go­ing some le­gis­lat­ive changes. An amend­ment thereto has been in­cluded in a lar­ger le­gis­lat­ive pack­age deal­ing with the reg­u­la­tion of med­ic­al devices. ...
23 June 2020
Coronavir­us (COV­ID-19) and Pri­vacy
CMS has pub­lished data pro­tec­tion guid­ance for em­ploy­ers who are re­act­iv­at­ing their work­places, and those that did not shut down their on-site op­er­a­tions.
02 June 2020
CMS Ex­pert Guide to In­ter­na­tion­al Ar­bit­ra­tion
This CMS Ex­pert Guide con­tains an over­view of in­ter­na­tion­al ar­bit­ra­tion prac­tice and chapters on the law and prac­tice of ar­bit­ra­tion in jur­is­dic­tions covered.
06 April 2020
Czech drug au­thor­ity re­com­mend­a­tions on clin­ic­al tri­als
The Czech State In­sti­tute for Drug Con­trol (SUKL) re­cently pub­lished its opin­ion on on­go­ing clin­ic­al tri­als and clin­ic­al tri­als that have not yet star­ted in light of the COV­ID-19 situ­ation. With the ex­cep­tion...
20 April 2020
CEE Green­field Guide
This CMS guide is in­ten­ded to help po­ten­tial in­vestors un­der­stand what in­cent­ives are avail­able when in­vest­ing in the lead­ing coun­tries in CEE. Find out more.
02 June 2020
CMS Ex­pert Guide to pay­ment term le­gis­la­tion
03 April 2020
Em­ploy­ment "An­ti­vir­us" scheme
Cor­rect as of 10:00 CET, 2 April. This art­icle is not be­ing main­tained. The situ­ation re­gard­ing COV­ID-19 and the Czech Gov­ern­ment re­sponses to the pan­dem­ic con­tin­ue to de­vel­op. On 1 April, the Gov­ern­ment...
16 March 2020
Coronavir­us & con­tract breaches in Cent­ral East­ern Europe
The situ­ation with Cov­id-19 (Coronavir­us) is still de­vel­op­ing rap­idly and is be­ing fol­lowed with keen in­terest and ob­vi­ous con­cern. We already know that this glob­al pan­dem­ic will have a severe so­cial and eco­nom­ic im­pact, and gov­ern­ments will do everything
15 May 2020
CMS Ex­pert Guide to COV­ID-19 cor­por­ate crime & reg­u­lat­ory is­sues
02 April 2020
Czech pro­cure­ment rules waived for COV­ID-19 emer­gency med­ic­al sup­plies
In light of the state of emer­gency in the Czech Re­pub­lic de­clared on 12 March 2020, the Of­fice for the Pro­tec­tion of Com­pet­i­tion of the Czech Re­pub­lic is­sued a state­ment that pro­cure­ment rules can be...